Skip to main content
. 2017 Jun 22;117(3):409–420. doi: 10.1038/bjc.2017.191

Figure 4.

Figure 4

MELK, NCAPG, BUB1, and CDK1 expression and clinical parameters. (A) The expression levels of MELK, NCAPG, BUB1, and CDK1 were significantly elevated as tumour stage increased. (B) The expression levels of MELK, NCAPG, BUB1, and CDK1 were significantly elevated in N1 stage PCa compared with that in N0 stage PCa. (C) Higher expression of MELK, NCAPG, BUB1, and CDK1 was associated with shorter BCR-free survival. (D) Multivariate Cox proportional hazards models were used to assess independent predictors of progression-free survival, including gene expression level (Z score > 0 vs Z score ⩽ 0), tumour stage (⩾ T3a vs ⩽ T2c), lymph node stage (N0 vs N1), and age at diagnosis (> 60 vs ⩽ 60). *P<0.05, **P<0.01, ***P<0.001.